Antiemesis

Ettinger, David S.; Armstrong, Debra; Barbour, Sally Y.; Berger, Mitchell B.; Bierman, Philip J.; Bradbury, Bob; Ellis, Georgiana K.; Kirkegaard, Steve; Kloth, Dwight D.; Kris, Mark G.; Lim, Dean; Michaud, Laura Boehnke; Nabati, Lida; Noonan, Kim; Rugo, Hope S.; Siler, Darby; Sorscher, Steven; Stelts, Sundae; Stucky-Marshall, Lisa; Todaro, Barbara; Urba, Susan G.

doi:10.6004/jnccn.2012.0047

Cited by 51 publications

(44 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To assess the compliance of China's antiemetic therapy regimens with published guidelines, we used those of NCCN and the Multinational Association of Supportive Care in Cancer (MASCC), as these had clearly defined recommendations for treatment of acute and delayed CINV in patients undergoing HEC and MEC (9,10). To treat acute and delayed CINV, the guidelines recommend that patients receiving HEC and MEC be treated with multiple prophylactic antiemetics.…”

Section: Discussionmentioning

confidence: 99%

“…Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China developed to promote the optimal use of antiemetics to prevent CINV (8)(9)(10)(11). These guidelines are specific to chemotherapies that are considered to have a high (>90%), moderate (30-90%), low (10-30%), or minimal (<10%) risk of triggering CINV.…”

Section: Original Articlementioning

confidence: 99%

See 1 more Smart Citation

Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China

Zong¹,

Zhang²,

Ji³

et al. 2016

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Background: Few studies have attempted to evaluate the use of antiemetic therapy for chemotherapyinduced nausea and vomiting (CINV) at a national level in China or to assess how treatment regimens adhere to current guidelines. Methods:We searched the China Health Insurance Research Association (CHIRA) Database to identify patients with cancer who were ≥18 years old and received either moderately or highly emetogenic chemotherapy (MEC and HEC, respectively) between 2008 and 2012. Patients' characteristics as well as usage of specific antiemetic regimens were analyzed using descriptive statistics.Results: Of the 14,548 patients included in the study, 6,477 received HEC while 8,071 were treated with MEC. Approximately 89.9% used antiemetics prophylactically to prevent acute CINV and 71.5% for delayed CINV while 9.0% were prescribed antiemetics as rescue therapy. A significantly lower proportion of patients treated with HEC received prophylactic antiemetic therapy for delayed CINV as compared to those treated with MEC (59.4% vs. 81.3%; P<0.001). The HEC group had a slightly lower proportion of patients using a mixed regimen containing a 5-HT3 antagonist to prevent both acute and delayed CINV than the MEC group (P≤0.012); however, a higher proportion received a mixed regimen containing corticosteroids (P≤0.007). Although more than half of the patients in the HEC group took three antiemetics to prevent acute and delayed CINV, these rates were significantly lower than those of the MEC group (both P<0.001).Finally, analysis of the regimens used revealed that there is over-utilization of drugs within the same class of antiemetic.Conclusions: These findings indicate that more attention is needed for treatment of delayed CINV, in terms of both overall use and the components of a typical treatment regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Original Articlementioning

confidence: 99%

Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China

Zong¹,

Zhang²,

Ji³

et al. 2016

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…Consistent with the trend reported by two previous studies (Almazron and Alnaim, 2012;Burmeister et al, 2012), it appears to be overprescribed for low emetogenic chemotherapy (LEC) among some of the general hospitals in Malaysia. In fact, it is only recommended to be used as the primary prophylaxis in moderately and highly-emetogenic chemotherapy (MEC and HEC) by both the local and international antiemetic guidelines (Ismail et al, 2011;Ettinger et al, 2012).…”

Section: Cost-effectiveness Analysis Of Granisetron-based Versus Stanmentioning

confidence: 99%

“…Due to a high degree of estimation involved, a variation of ±50% for cost (time) spent for clinical activities were applied. Cost changes due to two specific scenarios were also tested: if generic granisetron was used and granisetron dosage was reduced to 1mg as recommended by the updated guidelines (Ismail et al, 2011;Ettinger et al, 2012). Table 1 details the cost incurred in both granisetron and non-granisetron groups.…”

Section: Sensitivity Analysismentioning

confidence: 99%

Cost-Effectiveness Analysis of Granisetron-Based versus Standard Antiemetic Regimens in Low-Emetogenic Chemotherapy: A Hospital-based Perspective from Malaysia

Keat

Ghani²

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: In a prospective cohort study of antiemetic therapy conducted in Malaysia, a total of 94 patients received low emetogenic chemotherapy (LEC) with or without granisetron injections as the primary prophylaxis for chemotherapy-induced nausea and vomiting (CINV). This study is a retrospective cost analysis of two antiemetic regimens from the payer perspective. Materials and Methods: This cost evaluation refers to 2011, the year in which the observation was conducted. Direct costs incurred by hospitals including the drug acquisition, materials and time spent for clinical activities from prescribing to dispensing of home medications were evaluated (MYR 1=$0.32 USD). As reported to be significantly different between two regimens (96.1% vs 81.0%; p=0.017), the complete response rate of acute emesis which was defined as a patient successfully treated without any emesis episode within 24 hours after LEC was used as the main indicator for effectiveness. Results: Antiemetic drug acquisition cost per patient was 40.7 times higher for the granisetron-based regimen than for the standard regimen (MYR 64.3 vs 1.58). When both the costs for materials and clinical activities were included, the total cost per patient was 8.68 times higher for the granisetron-based regimen (MYR 73.5 vs 8.47). Considering the complete response rates, the mean cost per successfully treated patient in granisetron group was 7.31 times higher (MYR 76.5 vs 10.5). The incremental cost-effectiveness ratio (ICER) with granisetron-based regimen, relative to the standard regimen, was MYR 430.7. It was found to be most sensitive to the change of antiemetic effects of granisetron-based regimen. Conclusions: While providing a better efficacy in acute emesis control, the low incidence of acute emesis and high ICER makes use of granisetron as primary prophylaxis in LEC controversial.

show abstract

“…3) Furthermore, the prevalence of hyponatremia is high among cancer patients, which indicates that patients with hyponatremia may frequently receive chemotherapy. 12) However, the association between the incidence of CINV and hyponatremia remains unclear, and it would be useful to understand whether serum sodium concentrations in‰uence CINV among patients receiving chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Effects of Serum Sodium Concentrations on Nausea and Vomiting after Moderately Emetogenic Chemotherapy

Hatakeyama

Suzuki²,

Abe³

et al. 2018

YAKUGAKU ZASSHI

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) is the most unbearable adverse eŠect of chemotherapy. The antiemesis guidelines of the National Comprehensive Cancer Network indicate that hyponatremia is a risk factor for CINV, although the relationship between the incidence of CINV and hyponatremia has not been su‹ciently studied. This two-center prospective observational study evaluated whether low serum sodium concentrations were a risk factor for CINV. The study included 34 patients who were scheduled to receiveˆrst-line carboplatin-or oxaliplatin-based chemotherapy for gynecological or colorectal cancers. Patient diaries were used to record the daily incidences of CINV events during a 5-day period. The patients were divided based on the median serum sodium concentration into a low Na ＋ group (＜141 mEq/L) and a high Na ＋ group (141 mEq/L). The incidences of delayed nausea were 27.8％ in the high Na ＋ group and 62.5％ in the low Na ＋ group ( p＝0.042), with complete control rates (no vomiting, rescue medication, or grade 2 nausea) of 77.8％ and 43.8％, respectively ( p＝0.042). The time to complete control failure in each group was analyzed using the Kaplan-Meier method, which revealed a signiˆcantly shorter time in the low Na ＋ group ( p＝0.03). Therefore, these results indicate that low serum sodium concentrations may increase the risk of CINV.

show abstract

Antiemesis

Cited by 51 publications

References 84 publications

Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China

Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China

Cost-Effectiveness Analysis of Granisetron-Based versus Standard Antiemetic Regimens in Low-Emetogenic Chemotherapy: A Hospital-based Perspective from Malaysia

Effects of Serum Sodium Concentrations on Nausea and Vomiting after Moderately Emetogenic Chemotherapy

Contact Info

Product

Resources

About